Repligen Corporation (NASDAQ:RGEN) Stock Has Consensus Price Target of $168.57 According to Brokerages

Key Points

• Analyst sentiment is bullish: Eighteen brokerages give Repligen a consensus “Buy” rating, with an average 12-month price target of $168.57.
• Institutional ownership is high: Hedge funds have made significant additions to their positions, and institutional investors collectively own 97.64% of the company’s stock.
• Quarterly results exceeded expectations: Repligen reported EPS of $0.54 versus the $0.45 consensus estimate and revenue of $204.13 million, up 11.9% year over year.

Shares of Repligen Corporation (NASDAQ:RGEN - Get Free Report) have earned a consensus rating of "Buy" from the eighteen brokerages that are presently covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation, twelve have issued a buy recommendation and three have assigned a strong buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $168.57.

RGEN has been the topic of several analyst reports. Benchmark raised Repligen from a "hold" rating to a "buy" rating and set a $185.00 target price on the stock in a research report on Tuesday, July 7th. Wolfe Research started coverage on Repligen in a research report on Tuesday, June 2nd. They issued an "outperform" rating and a $145.00 price target for the company. Wells Fargo & Company lifted their price objective on shares of Repligen from $180.00 to $185.00 and gave the stock an "overweight" rating in a research note on Thursday, July 30th. Zacks Research upgraded shares of Repligen from a "hold" rating to a "strong-buy" rating in a research report on Thursday, July 30th. Finally, JPMorgan Chase & Co. increased their target price on shares of Repligen from $165.00 to $175.00 and gave the company an "overweight" rating in a research note on Wednesday, July 29th.

Hedge Funds Weigh In On Repligen

Several hedge funds have recently added to or reduced their stakes in the company. United Capital Financial Advisors LLC bought a new stake in Repligen in the second quarter worth about $380,756,000. Wasatch Advisors LP grew its stake in shares of Repligen by 27.9% during the second quarter. Wasatch Advisors LP now owns 1,590,251 shares of the biotechnology company's stock valued at $216,974,000 after buying an additional 346,720 shares during the last quarter. Maverick Capital Ltd. purchased a new stake in shares of Repligen in the first quarter worth approximately $178,946,000. Conestoga Capital Advisors LLC raised its holdings in shares of Repligen by 3.8% in the first quarter. Conestoga Capital Advisors LLC now owns 1,097,783 shares of the biotechnology company's stock worth $129,341,000 after buying an additional 39,808 shares during the period. Finally, Fred Alger Management LLC lifted its stake in shares of Repligen by 154.3% during the 4th quarter. Fred Alger Management LLC now owns 911,527 shares of the biotechnology company's stock worth $149,363,000 after acquiring an additional 553,105 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

Repligen Trading Up 2.3%

RGEN opened at $194.09 on Tuesday. The firm has a market cap of $10.95 billion, a P/E ratio of 265.88, a P/E/G ratio of 3.46 and a beta of 1.05. Repligen has a 12 month low of $100.99 and a 12 month high of $198.87. The company has a current ratio of 9.05, a quick ratio of 7.64 and a debt-to-equity ratio of 0.26. The stock has a 50-day moving average of $166.40 and a 200 day moving average of $139.51.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.45 by $0.09. The business had revenue of $204.13 million for the quarter, compared to the consensus estimate of $201.59 million. Repligen had a return on equity of 5.30% and a net margin of 5.29%.The company's quarterly revenue was up 11.9% compared to the same quarter last year. During the same period in the prior year, the business posted $0.26 earnings per share. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. As a group, research analysts forecast that Repligen will post 2.06 EPS for the current year.

About Repligen

Repligen Corporation NASDAQ: RGEN develops and supplies bioprocessing technologies used by biopharmaceutical manufacturers to develop and produce biologic drugs. Its products are designed to support key stages of biomanufacturing, including upstream processing, downstream purification, filtration, and process monitoring.

The company's portfolio includes chromatography products, filtration and single-use systems, process analytics technologies, and recombinant proteins such as Protein A-based products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.